Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Valproate-induced hyperammonemia.

M L Batshaw, S W Brusilow

    Annals of Neurology
    |March 1, 1982
    PubMed
    Summary
    This summary is machine-generated.

    Valproate (VPA) treatment can cause hyperammonemia, a condition of high ammonia levels, in patients with urea synthesis disorders. Monitor ammonia levels in patients on VPA experiencing vomiting or lethargy.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Sustained correction of OTC deficiency in spf( ash) mice using optimized self-complementary AAV2/8 vectors.

    Gene therapy·2011
    Same author

    Effect of glutamine synthetase inhibition on astrocyte swelling and altered astroglial protein expression during hyperammonemia in rats.

    Neuroscience·2005
    Same author

    Differences in the human and mouse amino-terminal leader peptides of ornithine transcarbamylase affect mitochondrial import and efficacy of adenoviral vectors.

    Human gene therapy·2001
    Same author

    Prospects for prenatal gene therapy in disorders causing mental retardation.

    Mental retardation and developmental disabilities research reviews·2001
    Same author

    Long-term gene transfer to mouse fetuses with recombinant adenovirus and adeno-associated virus (AAV) vectors.

    Gene therapy·2001
    Same author

    Alternative pathway therapy for urea cycle disorders: twenty years later.

    The Journal of pediatrics·2001
    Same journal

    Reply to "Clinical Value of Aneurysm Wall Enhancement in Unruptured Intracranial Aneurysm".

    Annals of neurology·2026
    Same journal

    Clinical Value of Aneurysm Wall Enhancement in Unruptured Intracranial Aneurysm.

    Annals of neurology·2026
    Same journal

    Imaging of Neurovascular Compression in Thoracic Outlet Syndrome.

    Annals of neurology·2026
    Same journal

    Reply to "Methodological Challenges in Interpreting SAA-Defined Imaging Subgroups in Parkinson's Disease".

    Annals of neurology·2026
    Same journal

    Methodological Challenges in Interpreting SAA-Defined Imaging Subgroups in Parkinson's Disease.

    Annals of neurology·2026
    Same journal

    The Financial Value of an Academic Neurologist.

    Annals of neurology·2026
    See all related articles

    Area of Science:

    • Biochemistry
    • Neurology
    • Pharmacology

    Background:

    • Valproate (VPA) is a widely used anticonvulsant medication.
    • Carbamyl phosphate synthetase deficiency is an inherited urea cycle disorder.
    • Hyperammonemia, elevated plasma ammonia, can lead to severe neurological complications.

    Observation:

    • A patient with carbamyl phosphate synthetase deficiency experienced recurrent symptomatic hyperammonemia during VPA treatment.
    • Epileptic patients on VPA showed higher mean plasma ammonium levels compared to those on other anticonvulsants.
    • Symptoms associated with hyperammonemia included vomiting, lethargy, and coma.

    Findings:

    • VPA treatment can precipitate symptomatic hyperammonemia in individuals with underlying urea synthesis pathway defects.

    Related Experiment Videos

  • VPA is associated with mildly elevated plasma ammonium levels in the general epileptic population.
  • The severity of hyperammonemia appears correlated with the degree of urea synthesis impairment.

    • Implications:

    • Clinicians should consider monitoring plasma ammonium levels in patients receiving VPA, especially those with pre-existing metabolic conditions or presenting with neurological symptoms like vomiting or lethargy.
    • This highlights the importance of understanding drug-induced metabolic disturbances in patient care.
    • Further research may elucidate the precise mechanisms by which VPA affects ammonia metabolism in diverse patient groups.